hydration effects glp-1 receptor agonists weight loss Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society Clinical Recommendations to Manage Gastrointestinal

The same injection site principles that apply to tirzepatide work for semaglutide: abdomen, thigh, or upper arm with consistent rotation to minimize injection site reactions

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes and obesity, yet their long-term cardiovascular effects in high-risk populations continue to be actively evaluated

Inability to consume adequate calories despite dietary strategies

GLP-1RA Liraglutide Semaglutide Efpeglenatide Glucose lowering effect CV system protection effect Kidney protection effect Nonalcoholic fatty liver disease GIP/GLP1 receptor coagonists: tirzepatide Amylin/GLP1 receptor coagonists: CagriSema (cagrilintide+semaglutide) Glucagon/GLP1 receptor coagonists: survodutide GIP/GLP1/glucagon receptor triple coagonists: retatrutide Obesity is a disease that can be treated with targeted pharmacotherapy in addition to lifestyle modification and behavioral interventions